This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrial fibrillation and heartfailure.
Heartfailure with preservedejectionfraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology. Notably, selective ablation of XBP1 in T cells enhanced their persistence in the heart and lymphoid organs of mice with preclinical HFpEF.
Patients who undergo catheter ablation for atrial fibrillation (AFib) who also have heartfailure with preservedejectionfraction (HFpEF) experienced a greater benefit from ablation in terms of clinical outcome, AFib recurrence and functional status, according to findings from the CABANA trial.
Clinical outcomes among patients with atrial fibrillation (AF) and heartfailure with preservedejectionfraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.
This randomized clinical trial investigates the feasibility, safety, and efficacy of endovascular right-sided splanchnic nerve ablation for volume management in heartfailure with preservedejectionfraction (HFpEF).
Atrial fibrillation (AF) is a common arrhythmia in patients with heartfailure (HF). Catheter ablation of AF has been proven to be an effective therapeutic option for AF management in HF, particularly in heartfailure with reduced ejectionfraction (HFrEF) [2, 3].
The efficacy of catheter ablation as a treatment approach for patients with concurrent atrial fibrillation (AF) and heartfailure with preservedejectionfraction (HFpEF) has been inadequately investigated.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heartfailure with preservedejectionfraction (HFpEF).
The benefit of catheter ablation in patients with atrial fibrillation (AF) for patients with heartfailure with preservedejectionfraction (HFpEF) remains uncertain.
Left atrial and pulmonary artery pressure (PAP) elevation can reflect severity and dynamic status of heartfailure (HF) in HF with preservedejectionfraction (pEF). Atrial fibrillation (AF) worsens HFpEF progression and pump failure, but catheter ablation can restore rhythm control in this population.
The HFA–PEFF score comprising echocardiographic and laboratory data is designed to diagnose heartfailure with preservedejectionfraction and holds prognostic value in patients who underwent catheter ablation for atrial fibrillation (AF).
Abstract Background Heartfailure (HF) with preservedejectionfraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. However, it remains unclear whether SRM after a repeat CA for recurrent AF has the same effect as SRM after the initial CA in patients with AF and HFpEF.
The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heartfailure and preservedejectionfraction (HFpEF) remains unclear.
Splanchnic ablation for volume management (SAVM) in heartfailure with preservedejectionfraction (HFpEF) was discussed as a late-breaking trial at the HeartFailure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
Previous studies have demonstrated significant morbidity and mortality in patients with heartfailure (HF) with reduced ejectionfraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
Catheter ablation has become the most effective rhythm control strategy in treating atrial fibrillation (AF), preventing AF recurrence and delaying its progression to persistent AF better than antiarrhythmic drugs.
A number of studies have examined the impact of atrial fibrillation (AF) ablation on outcomes in heartfailure (HF) with reduced ejection (HFrEF) patients. In contrast, data from HF with preservedejectionfraction (HFpEF) patients is limited to small outcome studies and less robust meta-analyses.
Studies have shown an overriding benefit of AF ablation in patients with long-standing HFrEF and symptomatic AF. Therefore, this study assesses whether the sequence of HFpEF and AF diagnoses influence mortality and HF progression risk and the subsequent impact of AF ablation.
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with HeartFailure With PreservedEjectionFraction, (..)
Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heartfailure (HF) hospitalization in patients with HF with preservedejectionfraction (HFpEF). However, the long-term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated.
Abstract Aims Atrial fibrillation (AF) is common in heartfailure (HF) and negatively impacts outcomes. The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejectionfraction (HFmrEF) is not known.
Background The HeartFailure Association Pretest assessment, echocardiography and natriuretic peptide, functional testing and final aetiology (HFA-PEFF) score has been developed for diagnosing heartfailure with preservedejectionfraction (HFpEF), which is frequently associated with atrial fibrillation (AF).
LVH is a common etiology of heartfailure with preservedejectionfraction, as it may results in a stiff ventricle with poor diastolic relaxation. LVH can have very thick-walled ventricles and a correspondingly small LV cavity. Figure-2: Part 1 — from the Review of HCM Treatment by Jacoby et al ( ACC.23/WCC
BackgroundHeart failure with preservedejectionfraction (HFpEF) and atrial fibrillation (AF) often coincide. Female sex is associated with both increased prevalence of HFpEF and reduced therapeutic efficacy of catheter ablation of AF. Forty-two were female. ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2, ml/m2 vs. 25.8 ml/m2,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content